Nanoparticles: a new frontier in neurodegenerative disease therapy
Kumar V., Sharma S., Singh A.
Narrative Review on Neuroinflammation, published in Front Med Technol (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Front Med Technol (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41356731
- PMCID
- PMC12675484
- DOI
- 10.3389/fmedt.2025.1654003
- Citations
- 3
Abstract (original English)
Nanoparticle-based drug delivery systems, such as liposomes, polymeric micelles, dendrimers, and other nanosized carriers, have emerged as promising strategies to improve the targeted delivery of therapeutic agents to the brain. These nanoparticles can be engineered to encapsulate drugs, facilitating their passage across the BBB, enabling localized treatment of the regions affected by neurodegeneration. Nanoparticles are characterized by their small size, large surface area, and possibility of functionalization, which allows them to be useful in many areas, including improved bioavailability, decreased systemic side effects, and improved therapeutic efficacy. Additionally, nanoparticles may also be surface-modified with appropriate ligands like antibodies, peptides, or small molecules, which exhibit specific interactions with receptors or cellular targets associated with the disease process. Such targeting has the potential to make targeted drug delivery possible, allowing therapeutic factors that can damage the healthy part of the brain to be delivered only to the diseased region. Furthermore, probable treatments for neurodegenerative diseases are also reviewed with the potential for complexation of different therapeutic agents, including small molecules, proteins, RNA, lipid nanoparticles and gene therapies with nanoparticle-based systems.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewPubMed
Adipose-Derived Stem Cells in Traumatic Brain Injury: A Systematic Review of Preclinical Studies.
Systematic Review on Neuroinflammation, published in Tissue Eng Regen Med (2026) — summary generated from the PubMed abstract.
- 2026
Tissue Eng Regen Med - Level ASystematic ReviewPubMed
The use of cellular therapies for trigeminal neuralgia: a systematic review of behavioral and molecular outcomes.
Systematic Review with a reported sample of 8 on Neuroinflammation, published in Neurosurg Rev (2026) — summary generated from the PubMed abstract.
- 2026
- n = 8
Neurosurg Rev - Level ASystematic ReviewEurope PMC
Factor XII-A New Therapeutic Target? A Systematic Review
Systematic Review on Cardiovascular Disease, Neuroinflammation, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.
- 2026
Int J Mol Sci1 citations - Level ASystematic ReviewEurope PMC
Efficacy of Exosome-Based Therapies for Skin Rejuvenation: A Systematic Review of Human Studies
Systematic Review on Neuroinflammation, Skin Aging, published in Cureus (2026) — summary generated from the PubMed abstract.
- 2026
Cureus - Level ASystematic ReviewEurope PMC
Harnessing exosomes in dry eye disease: a triple threat approach
Systematic Review on Neuroinflammation, Chronic Inflammation, Immune Modulation, published in BMC Ophthalmol (2026) — summary generated from the PubMed abstract.
- 2026
BMC Ophthalmol - Level ASystematic ReviewEurope PMC
Safety and Efficacy of Mesenchymal Stem Cell Therapy in Multiple System Atrophy: Systematic Review
Systematic Review with a reported sample of 123 on Neuroinflammation, Chronic Inflammation, Immune Modulation, published in Biologics (2026) — summary generated from the PubMed abstract.
- 2026
- n = 123
Biologics